EP0214167A1 - Method for the determination of antibodies or antigens - Google Patents

Method for the determination of antibodies or antigens

Info

Publication number
EP0214167A1
EP0214167A1 EP19860901081 EP86901081A EP0214167A1 EP 0214167 A1 EP0214167 A1 EP 0214167A1 EP 19860901081 EP19860901081 EP 19860901081 EP 86901081 A EP86901081 A EP 86901081A EP 0214167 A1 EP0214167 A1 EP 0214167A1
Authority
EP
European Patent Office
Prior art keywords
particles
layer
fluorescent
reaction
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP19860901081
Other languages
German (de)
French (fr)
Inventor
Juhani E.I. Luotola
Hannu Harjunmaa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thermo Fisher Scientific Oy
Original Assignee
Labsystems Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Labsystems Oy filed Critical Labsystems Oy
Publication of EP0214167A1 publication Critical patent/EP0214167A1/en
Ceased legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326Magnetic particles
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex

Definitions

  • the present invention is concerned with a fluoro etric or phosphorimetric iirununoassay method in which small polymer particles are used as the solid phase.
  • the method in accordance with the invention can be used, besides for immunoassays in general, also for blood group determinations.
  • the signal concerned may be, e.g., radioactivity (RIA), fluores ⁇ cence signal (FIA) or even enzyme activity (EIA, i.e. Enzyme Immunoassay) .
  • RIA radioactivity
  • FIA fluores ⁇ cence signal
  • EIA enzyme activity
  • the separation of the solid phase from the reaction solution always includes washing of the solid phase, which, at present, requires operations whose automation is difficult. Thus, these operations are, as a rule, carried out manually. If small polymer particles are used, the operations include centrifuging or mag ⁇ netic deposition.
  • the principal objective of the present inven ⁇ tion is to provide such a method for the determination of antibodies or antigens in which inconvenient operations of separation are avoided and which is also suitable for being used in connection with such antibodies or anti ⁇ gens as are placed on the surface of cells or other particles of organic origin.
  • particles treated with a fluorescent (or phosphorescent) tracer are, together with particles treated with a magnetic material, immobilized on an antibody (or antigen) by means of an antigen-antibody bond.
  • the cells and the magnetic and fluorescent particles attached to them are pulled by means of a magnetic field from the reaction layer into the separation layer, whereupon the fluorescence is determined from the separation layer or from the reaction layer. Fluorescence is emitted only if the excitation light meets fluorescent particles. Mere magnetic particles alone do not emit fluorescent radiation.
  • the antibody does not become labelled with the polymer particles covered by the antigen concerned, only the magnetic particles arrive in the separation layer, and the fluorescent non-magnetic particles and the unlabelled cells remain behind the separation layer.
  • the method is suitable for being used both as a direct method and as an indirect method. Thereat, for example, the determination of blood group can be carried out both from the cell side and from the serum side. The determination from the serum side takes place as indirect.
  • the method in accordance with the invention is easy to carry out, because the solutions do not have to be removed from the vessel and because no separate washings have to be carried out.
  • Figures 1 to 4 illustrate the determination of dissolved antibody.
  • Figures 5 to 8 illustrate the de ⁇ termination of an antigen placed on the surface of a cell
  • Figures 9 and 10 illustrate simultaneous de ⁇ termination of several antibodies.
  • Figures 1 to 4 illustrate the determination of dissolved antibody.
  • a reaction layer 1 In the measurement vessel, there are two liquid layers (Fig. 1) : a reaction layer 1 and a so-called separation layer 2.
  • the reaction layer 1 In the reaction layer 1, there is the antibody 3 to be determined, in dissolved form.
  • the reaction layer 1 there are polymer particles covered with antigen 4 of the antibody 3, of which said polymer particles the particles 5 include a magnetic material and the particles 6 include a fluores ⁇ cent tracer.
  • the polymer particles are pearls made of some suitable material, and their size is 0.1 to 10 ⁇ m.
  • the separation layer 2 is placed in the vessel below the reaction layer 1. It has been placed into the vessel before the reaction layer 1 , or it has been added afterwards to underneath the reaction layer.
  • the separation liquid 2 is preferably denser than the reaction solution 1 , and of such a colour that it prevents the fluorescence in the -reaction solution from being seen in the measurement.
  • Suitable reaction solutions are, e.g., saccharose solution (concentration typically 10 to 60 %) and Ficoll-Paque density-gradient centrifuging solution, etc. If the separation solution is not of suitable colour by nature, a suitable colour is obtained by to it adding a colouring agent which ab ⁇ sorbs " light strongly within the excitation or emission wavelength of fluorescence, or within both wavelengths. In particular, black is a suitable colour.
  • the conventional incubation stage follows, whereat the immunological reaction takes place (Fig. 2) .
  • the antibody 3 to be determined is bound with the antigen 4 placed on the surface both of the magnetic 5 and of the fluorescent 6 particle.
  • the antibody 3 can now be both displaced magnetically and measured fluorometri- cally. If there is no antibody 3 in the sample, only the magnetic particles 5 can be displaced magnetically.
  • the magnetic particles 5 are pulled by means of a magnetic field 7 through the separation layer 2 onto the bottom of the measurement vessel (Fig. 3) .
  • the fluorescent particles 6 adhering to the magnetic particles by the intermediate of the antibody, follow along with them.
  • the separation layer 2 also acts as a physico-chemical washing layer.
  • a particular magnetic separation device is built in. The more of the antibody 3 to be determined there is present in the sample, the more particles 6 covered with the fluorescent tracer are there now on the bottom of the vessel.
  • the measurement takes place so that the exci ⁇ tation radiation 8 is passed to the bottom of the measure ⁇ ment vessel through its wall, and the emission radiation 9 is also collected along the same route for detection (Fig. 4) .
  • the coloured separation layer 2 now acts as an optical shield layer against viewing of the fluorescent reaction layer 1. Thereby, no emitted fluorescent radiation has access from the reaction layer 1 into the detector system, and only the fluorescent particles placed on the bottom of the vessel are detected.
  • Figures 5 to 8 illustrate a case in which an antigen placed on the surface of a cell is to be de ⁇ termined.
  • the measurement vessel there is also a reaction layer 1 at the top and a separation layer 2 underneath.
  • the reaction layer 1 there are cells -10 on whose surface there is antigen 11. More ⁇ over, in the reaction layer, there are polymer particles covered with the antibody 12 of the said antigen, some of the said polymer particles being magnetic 5, and some of them being fluorescent 6.
  • the dosage stage Fig. 5
  • the incubation stage Fig. 6
  • the separation stage Fig. 7
  • the measurement stage Fig. 8
  • This method can be applied, e.g., to b ood group determinations as follows:
  • mag- netic and fluorescent particles covered with a known antibody are measured (the same antibody on the surface of each particle type) . It is assumed that in the mea ⁇ surement vessel A there are magnetic and fluorescent particles covered with anti-A antibody, and in the mea- surement vessel B there are magnetic and fluorescent particles covered with anti-B antibody.
  • both of the particle types, magnetic and fluorescent adhere to the same .cell.
  • none of the particle types adheres to the cell surface, whereby only the magnetic particles respond to the magnetic field.
  • the magnetized particles and the labelled cells, if any, are pulled against the bottom of the measurement vessel.
  • the determination of the blood group is performed by in con ⁇ nection with the incubation adding a serum sample to be studied on the basis of known control cells (A and B cells) and corresponding magnetic anti-A and anti-B particles. If in the reaction vessel A the adherence of anti-A particles is prevented and the signal is negative, there has been anti-A antibody present in the serum, which has acted on the basis of competition and prevented the adhesion of anti-A particles. ' If the reaction is posi ⁇ tive in respect of the anti-B particles present in the reaction vessel B, the blood group is B from the serum side.
  • the blood group is A from the serum side. If the signal is positive both in the reaction vessel A and in the reaction vessel B, the blood group is AB from the serum side. On the other hand, if the signal is negative in both of the reaction vessels, the blood group is 0.
  • the blood group can be determined by covering the particles with the corresponding blood cell antigen, which are also available commercially. In the determination of anti- bodies, when particles covered with red-cell antigens are used, no test cells are needed at all. When cells are used, by means of inhibition it is possible to establish, e.g., a person's secretor property.
  • the method can also be carried out by means of competition by using magnetic and fluorescent particles covered with the same antigen in the same reaction vessel. If there is the corresponding antibody (IgM class) in the serum, fluorescent pearls are also deposited in con ⁇ nection with the magnetic pearls, being linked by the antibody.
  • IgM class antibody
  • the Rh-factor can be established by incubating the cells to be studied with anti-D serum. whereby the antibody adheres to the face of the red blood cell.
  • the antibody concerned is of the type IgG, which can be detected by means of anti-human-IgG.
  • the antibody may be attached to fluorescent particles, or it may be present as its fluorescent conjugate.
  • the methods may be the following: After red blood cells have been incubated in anti-D serum, magnetic pearls covered with anti-human-erythrocyte antibody are added to among the sensitized red blood cells, and the red blood cells are pulled down after the incubation time. Now it is possible to suck off any excess serum and unattached pearls out of the measurement vessel while keeping the magnetic field constantly on.
  • the cells can be washed in a suitable medium, while finally depositing the cells down by means of the magnetic field.
  • fluorescent pearls covered with anti-human-IgG and to underneath the mixture of cells and pearls, it is possible to add " a dense, coloured, suitable separating substance.
  • the cells are again pulled down by means of the magnetic field, whereby detection of the fluorescence is possible.
  • the coloured dense substance before the fluorescent particles, in which case the risk of fluo ⁇ rescence contamination is reduced.
  • One mode of labelling the Rh-positive cells is to sensitize the cells by means of anti-D, whereupon the cells are pulled by means of magnetic anti-human-erythrocyte particles into the first separation-substance layer, wherein there is a very large quantity of fluorescent particles covered with anti-human-IgG or of fluorescent anti-human- IgG conjugate.
  • the magnetic pulling is stopped at this layer for the time of the incubation, and upon completion of the incubation the cells are pulled through another coloured layer, of higher density, to the bottom of the measurement vessel, and the fluorescence is detected.
  • Fig. 9 illus- trates simultaneous determination of several antibodies in a case in which the antigens of all of the antibodies are attached onto the surfaces of magnetic particles of one sort.
  • Fig. 10 illustrates simultaneous determination of several antibodies in a case in which the antigen of each antibody is attached onto the surface of the par ⁇ ticles in its own group of particles.
  • the reaction solution there are magnetic particles 5, 5' and 5", one antigen, either 4, 4' or 4", being attached to the surface of each of the said par- ticles.
  • fluorometric measurement is carried out at each of the wavelengths concerned in order to determine the anti ⁇ bodies 3, 3' and 3".
  • the methods described above can, of course, also be applied by making use of phosphorescence.
  • the methods in the solid phase, there may be an antibody equally well as an antigen.
  • the separation layer may be placed on top of the reaction layer. In such a case, the measurement becomes less convenient, but thereby the background fluorescence caused by the vessel wall is avoided. If desired, the separation layer may also be formed in the vessel after the incubation.
  • the measurement may also be carried out from the reaction layer.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)

Abstract

Dans un procédé de dépistage d'anticorps, des particules fluorescentes (6) et magnétiques (5) sont ajoutées à l'échantillon, et l'antigène de l'anticorps (3) que l'on veut dépister est placé sur la surface des deux types de particules. Pendant une réaction immunologique, les particules fluorescentes adhèrent aux particules magnétiques par l'intermédiaire de l'anticorps. Après la réaction, les particules magnétiques sont attirées par un aimant dans une couche de séparation (2), dont la fluorescence est alors mesurée.In an antibody screening process, fluorescent (6) and magnetic (5) particles are added to the sample, and the antibody (3) antigen to be screened is placed on the surface of the cells. two types of particles. During an immunological reaction, the fluorescent particles adhere to the magnetic particles via the antibody. After the reaction, the magnetic particles are attracted by a magnet in a separation layer (2), the fluorescence of which is then measured.

Description

Method for the determination of antibodies or antigens
The present invention is concerned with a fluoro etric or phosphorimetric iirununoassay method in which small polymer particles are used as the solid phase. The method in accordance with the invention can be used, besides for immunoassays in general, also for blood group determinations.
In prior art, methods are known which are based on immobilization of an antibody or antigen on an antigen or antibody in advance placed on a solid face as well as on the use of an antibody or antigen labelled with a tracer. Such methods are, e.g., RIA (Radioi muno- assay) and SP-FIA (Solid Phase Fluoroimmunoassay) . In all of these methods, the solid face on which the immuno- logical reaction has taken place and the reaction solu¬ tion must be separated from each other before the signal of the tracer is measured in order that the excess tracer present in the reaction solution should not cover the signal of the tracer present in the antibody or antigen immobilized on the solid phase. The signal concerned may be, e.g., radioactivity (RIA), fluores¬ cence signal (FIA) or even enzyme activity (EIA, i.e. Enzyme Immunoassay) . The separation of the solid phase from the reaction solution always includes washing of the solid phase, which, at present, requires operations whose automation is difficult. Thus, these operations are, as a rule, carried out manually. If small polymer particles are used, the operations include centrifuging or mag¬ netic deposition.
The principal objective of the present inven¬ tion is to provide such a method for the determination of antibodies or antigens in which inconvenient operations of separation are avoided and which is also suitable for being used in connection with such antibodies or anti¬ gens as are placed on the surface of cells or other particles of organic origin.
In the assay method in accordance with the invention, particles treated with a fluorescent (or phosphorescent) tracer are, together with particles treated with a magnetic material, immobilized on an antibody (or antigen) by means of an antigen-antibody bond. After the immobilization of the particles, the cells and the magnetic and fluorescent particles attached to them are pulled by means of a magnetic field from the reaction layer into the separation layer, whereupon the fluorescence is determined from the separation layer or from the reaction layer. Fluorescence is emitted only if the excitation light meets fluorescent particles. Mere magnetic particles alone do not emit fluorescent radiation. If the antibody does not become labelled with the polymer particles covered by the antigen concerned, only the magnetic particles arrive in the separation layer, and the fluorescent non-magnetic particles and the unlabelled cells remain behind the separation layer. The method is suitable for being used both as a direct method and as an indirect method. Thereat, for example, the determination of blood group can be carried out both from the cell side and from the serum side. The determination from the serum side takes place as indirect. The method in accordance with the invention is easy to carry out, because the solutions do not have to be removed from the vessel and because no separate washings have to be carried out.
Certain preferred embodiments of the invention will be illustrated by means of the attached schematical Figures 1 to 10.
Figures 1 to 4 illustrate the determination of dissolved antibody. Figures 5 to 8 illustrate the de¬ termination of an antigen placed on the surface of a cell, and Figures 9 and 10 illustrate simultaneous de¬ termination of several antibodies. Figures 1 to 4 illustrate the determination of dissolved antibody.
In the measurement vessel, there are two liquid layers (Fig. 1) : a reaction layer 1 and a so-called separation layer 2. In the reaction layer 1, there is the antibody 3 to be determined, in dissolved form. Moreover, in the reaction layer 1 , there are polymer particles covered with antigen 4 of the antibody 3, of which said polymer particles the particles 5 include a magnetic material and the particles 6 include a fluores¬ cent tracer. The polymer particles are pearls made of some suitable material, and their size is 0.1 to 10 μm.
The separation layer 2 is placed in the vessel below the reaction layer 1. It has been placed into the vessel before the reaction layer 1 , or it has been added afterwards to underneath the reaction layer.
The separation liquid 2 is preferably denser than the reaction solution 1 , and of such a colour that it prevents the fluorescence in the -reaction solution from being seen in the measurement. Suitable reaction solutions are, e.g., saccharose solution (concentration typically 10 to 60 %) and Ficoll-Paque density-gradient centrifuging solution, etc. If the separation solution is not of suitable colour by nature, a suitable colour is obtained by to it adding a colouring agent which ab¬ sorbs" light strongly within the excitation or emission wavelength of fluorescence, or within both wavelengths. In particular, black is a suitable colour.
After the reaction layer and the sample layer have been measured into the measurement vessel, the conventional incubation stage follows, whereat the immunological reaction takes place (Fig. 2) . Thereby, the antibody 3 to be determined is bound with the antigen 4 placed on the surface both of the magnetic 5 and of the fluorescent 6 particle. The antibody 3 can now be both displaced magnetically and measured fluorometri- cally. If there is no antibody 3 in the sample, only the magnetic particles 5 can be displaced magnetically.
After the reaction has been completed, the magnetic particles 5 are pulled by means of a magnetic field 7 through the separation layer 2 onto the bottom of the measurement vessel (Fig. 3) . The fluorescent particles 6 , adhering to the magnetic particles by the intermediate of the antibody, follow along with them. At the same time, the separation layer 2 also acts as a physico-chemical washing layer. Into the flurometer used in the method, a particular magnetic separation device is built in. The more of the antibody 3 to be determined there is present in the sample, the more particles 6 covered with the fluorescent tracer are there now on the bottom of the vessel. The measurement takes place so that the exci¬ tation radiation 8 is passed to the bottom of the measure¬ ment vessel through its wall, and the emission radiation 9 is also collected along the same route for detection (Fig. 4) . The coloured separation layer 2 now acts as an optical shield layer against viewing of the fluorescent reaction layer 1. Thereby, no emitted fluorescent radiation has access from the reaction layer 1 into the detector system, and only the fluorescent particles placed on the bottom of the vessel are detected.
Figures 5 to 8 illustrate a case in which an antigen placed on the surface of a cell is to be de¬ termined.
In this case, in the measurement vessel there is also a reaction layer 1 at the top and a separation layer 2 underneath. In the reaction layer 1 , there are cells -10 on whose surface there is antigen 11. More¬ over, in the reaction layer, there are polymer particles covered with the antibody 12 of the said antigen, some of the said polymer particles being magnetic 5, and some of them being fluorescent 6. After the dosage stage (Fig. 5) , there are the incubation stage (Fig. 6) , the separation stage (Fig. 7) , and the measurement stage (Fig. 8) , in a way corres¬ ponding to the case described above, in which said case the antibody is present in the reaction solution in dis¬ solved form.
This method can be applied, e.g., to b ood group determinations as follows:
To among the blood cells to be studied, mag- netic and fluorescent particles covered with a known antibody are measured (the same antibody on the surface of each particle type) . It is assumed that in the mea¬ surement vessel A there are magnetic and fluorescent particles covered with anti-A antibody, and in the mea- surement vessel B there are magnetic and fluorescent particles covered with anti-B antibody. In connection with incubation, in a positive case, both of the particle types, magnetic and fluorescent, adhere to the same .cell. In the negative case, none of the particle types adheres to the cell surface, whereby only the magnetic particles respond to the magnetic field. The magnetized particles and the labelled cells, if any, are pulled against the bottom of the measurement vessel. When fluorescence is now measured through the bottom of the measurement vessel, only the fluorescent particles placed on the surface of the blood cells are noticed. If only the reaction vessel A gives a positive signal, the blood group is A from the cell side. If only the reaction vessel B gives a posi¬ tive signal, the blood group is B from the cell side. If both of the reaction vessels give positive signals, the blood group is AB from the cell side. If both of the reaction vessels give negative signals, the blood group is 0 from the cell side.
Correspondingly, from the serum side, the determination of the blood group is performed by in con¬ nection with the incubation adding a serum sample to be studied on the basis of known control cells (A and B cells) and corresponding magnetic anti-A and anti-B particles. If in the reaction vessel A the adherence of anti-A particles is prevented and the signal is negative, there has been anti-A antibody present in the serum, which has acted on the basis of competition and prevented the adhesion of anti-A particles. 'If the reaction is posi¬ tive in respect of the anti-B particles present in the reaction vessel B, the blood group is B from the serum side. On the other hand, if there is a positive signal in the reaction vessel A,but a negative signal in the re¬ action vessel B, the blood group is A from the serum side. If the signal is positive both in the reaction vessel A and in the reaction vessel B, the blood group is AB from the serum side. On the other hand, if the signal is negative in both of the reaction vessels, the blood group is 0.
Of course, in the method, it is possible to use all known blood cell and serum types with their sub¬ groups. Program-technically, in the blood-group assays, it is possible to take into account the safe lower and . upper limits. Moreover, from the serum side, the blood group can be determined by covering the particles with the corresponding blood cell antigen, which are also available commercially. In the determination of anti- bodies, when particles covered with red-cell antigens are used, no test cells are needed at all. When cells are used, by means of inhibition it is possible to establish, e.g., a person's secretor property.
The method can also be carried out by means of competition by using magnetic and fluorescent particles covered with the same antigen in the same reaction vessel. If there is the corresponding antibody (IgM class) in the serum, fluorescent pearls are also deposited in con¬ nection with the magnetic pearls, being linked by the antibody.
In the method, the Rh-factor can be established by incubating the cells to be studied with anti-D serum. whereby the antibody adheres to the face of the red blood cell. The antibody concerned is of the type IgG, which can be detected by means of anti-human-IgG. The antibody may be attached to fluorescent particles, or it may be present as its fluorescent conjugate. The methods may be the following: After red blood cells have been incubated in anti-D serum, magnetic pearls covered with anti-human-erythrocyte antibody are added to among the sensitized red blood cells, and the red blood cells are pulled down after the incubation time. Now it is possible to suck off any excess serum and unattached pearls out of the measurement vessel while keeping the magnetic field constantly on. When the magnetic field is switched off, the cells can be washed in a suitable medium, while finally depositing the cells down by means of the magnetic field. To among the washed sensitized cells, it is now possible to add fluorescent pearls covered with anti-human-IgG, and to underneath the mixture of cells and pearls, it is possible to add "a dense, coloured, suitable separating substance. Upon completion of the incubation, the cells are again pulled down by means of the magnetic field, whereby detection of the fluorescence is possible. Of course, it is also possible to add the coloured dense substance before the fluorescent particles, in which case the risk of fluo¬ rescence contamination is reduced. In place of the fluorescent particles, it is also possible to use a fluorescent anti-human-IgG conjugate. One mode of labelling the Rh-positive cells is to sensitize the cells by means of anti-D, whereupon the cells are pulled by means of magnetic anti-human-erythrocyte particles into the first separation-substance layer, wherein there is a very large quantity of fluorescent particles covered with anti-human-IgG or of fluorescent anti-human- IgG conjugate. The magnetic pulling is stopped at this layer for the time of the incubation, and upon completion of the incubation the cells are pulled through another coloured layer, of higher density, to the bottom of the measurement vessel, and the fluorescence is detected.
The techniques concerned can also be utilized in antibody screening and in a cross test. Fig. 9 illus- trates simultaneous determination of several antibodies in a case in which the antigens of all of the antibodies are attached onto the surfaces of magnetic particles of one sort.
In the reaction solution, there are magnetic particles 12, an antigen 4, 4' and 4" being attached to the surface of each of them. Moreover, in the reaction solution, there are fluorescent particles 6, 6' and 6", on whose surface there is only one antigen, either 4, 4' or 4", and each of which is provided with a characteristic fluorescent tracer of its own.
After the stages of incubation and separation have been carried out, measurement is carried out by using the specific excitation or emission wavelength of each of the fluorescent particles 6, 6', 6". In this way the desired antibodies 3, 3' and 3" can be determined.
Fig. 10 illustrates simultaneous determination of several antibodies in a case in which the antigen of each antibody is attached onto the surface of the par¬ ticles in its own group of particles. In the reaction solution, there are magnetic particles 5, 5' and 5", one antigen, either 4, 4' or 4", being attached to the surface of each of the said par- ticles. In the solution, there are also fluorescent particles 6, 6' and 6", each of which is provided with a typical tracer of its own.
After the stages of incubation and separation, fluorometric measurement is carried out at each of the wavelengths concerned in order to determine the anti¬ bodies 3, 3' and 3". The methods described above can, of course, also be applied by making use of phosphorescence. In the methods, in the solid phase, there may be an antibody equally well as an antigen.
If necessary, the separation layer may be placed on top of the reaction layer. In such a case, the measurement becomes less convenient, but thereby the background fluorescence caused by the vessel wall is avoided. If desired, the separation layer may also be formed in the vessel after the incubation.
Of course, if desired, the measurement may also be carried out from the reaction layer.

Claims

WHAT IS CLAIMED IS:
1. Fluorometric or phosphorimetric method for the determination of antibodies or antigens out of a sample by means of an immunological reaction, c h a r ¬ a c t e r i z e d in that to a sample placed in a measurement vessel in a layer (1) or reaction solution, particles (6) that include a fluorescent or phosphores¬ cent tracer as well as magnetic particles (5) are added, antigen of the antibody to be determined being placed on the surface of each of the said particles ; that in the measurement vessel, below or above the reaction layer, a separation solution layer (2) is formed that is not mixed with the reaction layer; that after the immuno- logical reaction, the magnetic particles with the fluorescent or phosphorescent particles linked to them by the intermediate of the antibody are pulled by means of a magnetic field into the separation -layer; whereupon the fluorescent or phosphorescent particles are deter- mined fluorometrically or phosphorimetrically out of the separation layer or out of the reaction layer.
2. Method as claimed in claim 1, c h a r ¬ a c t e r i z e d in that in the measurement vessel a separation layer (2) denser than the reaction layer (1) is formed below the reaction layer (1) and that the fluorescence or phosphorescence is measured out of the separation layer through the wall of the measurement vessel .
3. Method as claimed in claim 1, c h a r - a c t e r i z e d in that in the measurement vessel a separation layer (2) is formed, which absorbs strongly at the excitation or emission wavelength of the fluo¬ rescence or phosphorescence of the tracer, and that the magnetic particles (5) are pulled from the reaction layer (1) through the separation layer (2) to the opposite edge of the separation layer.
4. Method as claimed in claim 3 , c h a r ¬ a c t e r i z e d in that a separation layer (2) is formed which absorbs strongly both at the excitation wavelength and at the emission wavelength of the tracer.
5. Method as claimed in claim 4, c h a r ¬ a c t e r i z e d in that a black separation layer (2) is formed.
6. Method as claimed in claim 1 for the de¬ termination of several antibodies out of" one sample, c h a r a c t e r i z e d in that particles (6, 6', 6") that include a fluorescent or phosphorescent tracer are added to the sample, the surface of each particle being covered with the antigen (4, 4', 4") of one of the anti¬ bodies (3, 3' , 3") to be determined and each of the said particles having a tracer of its own, as well as that magnetic particles (5, 5', 5") are added to the sample, the surface of each of the magnetic particles being covered with the antigen of one of the antibodies to be determined, and that each of the fluorescent particles is determined separately at its specific wavelength.
7. Method as claimed in claim 1 for the de¬ termination of several antibodies out of one sample, c h a r a c t e r i z e d in that particles (6, 6', 6") that include a fluorescent tracer are added to the sample, the surface of each particle being covered with the antigen (4, 4', 4") of one of the antibodies (3, 3', 3") to be determined and each of the said particles having a tracer of its own, as well as that magnetic particles (12) are added to the sample, the surface of each of the magnetic particles being covered with antigens of all of the antibodies to be determined, and that each of the fluorescent particles is determined separately at its specific wavelength.
EP19860901081 1985-02-06 1986-02-05 Method for the determination of antibodies or antigens Ceased EP0214167A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI850481A FI850481A0 (en) 1985-02-06 1985-02-06 FOERFARANDE FOER BESTAEMNING AV MOTMEDEL ELLER ANTIGENER.
FI850481 1985-02-06

Publications (1)

Publication Number Publication Date
EP0214167A1 true EP0214167A1 (en) 1987-03-18

Family

ID=8520326

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19860901081 Ceased EP0214167A1 (en) 1985-02-06 1986-02-05 Method for the determination of antibodies or antigens

Country Status (4)

Country Link
EP (1) EP0214167A1 (en)
JP (1) JPS62501647A (en)
FI (1) FI850481A0 (en)
WO (1) WO1986004684A1 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071774A (en) * 1983-04-05 1991-12-10 Syntex (U.S.A.) Inc. Multiparameter particle analysis
AU7399487A (en) * 1986-05-22 1987-12-22 Unilever Plc Solid phase immunoassay method
US5238810A (en) * 1986-09-22 1993-08-24 Nippon Telegraph And Telephone Corporation Laser magnetic immunoassay method and apparatus thereof
EP0287665B1 (en) * 1986-09-22 1996-07-31 Nippon Telegraph And Telephone Corporation Laser magnetic immunoassay method and apparatus therefor
GB8717862D0 (en) * 1987-07-28 1987-09-03 Acade Diagnostic Systems Sa Nv Turbidimetric assay
CN1034617A (en) * 1987-10-09 1989-08-09 奈吉尼股份有限公司 Identify the method and the device of biochemical species
JPH05504828A (en) * 1988-05-04 1993-07-22 ケンブリッジ、バイオテック、コーポレーション Capillary flow device and dual capture assay method
US5145784A (en) * 1988-05-04 1992-09-08 Cambridge Biotech Corporation Double capture assay method employing a capillary flow device
DE3840462A1 (en) * 1988-12-01 1990-06-07 Berthold Lab Prof R METHOD AND DEVICE FOR MEASURING CHEMILUMINESCENCE
JP2910929B2 (en) * 1989-03-23 1999-06-23 浜松ホトニクス株式会社 Surface modification method for particles composed of magnetic particles
GB2236852B (en) * 1989-09-25 1994-04-06 Scotgen Ltd DNA probe based assays and intermediates useful in the synthesis of cleavable nucleic acids for use in such assays
US5279936A (en) * 1989-12-22 1994-01-18 Syntex (U.S.A.) Inc. Method of separation employing magnetic particles and second medium
GB2270976A (en) * 1992-09-18 1994-03-30 Marconi Gec Ltd Immunoassay/separation process using an auxiliary species on a support
EP0660935B1 (en) * 1992-08-03 2000-05-24 Gec-Marconi Limited Immunological detection using two detectable labels
GB2270158B (en) * 1992-08-03 1997-03-19 Marconi Gec Ltd Detection
US5374531A (en) * 1993-03-22 1994-12-20 Zynaxis, Inc. Immunoassay for determination of cells
AUPN214095A0 (en) 1995-04-03 1995-04-27 Australian Water Technologies Pty Ltd Method for detecting microorganisms using flow cytometry
EP1428018B1 (en) 2001-09-06 2010-06-09 Straus Holdings Inc. Rapid and sensitive detection of molecules
US7018849B2 (en) 2002-01-15 2006-03-28 Piasio Roger N Process for (A) separating biological/ligands from dilute solutions and (B) conducting an immunochromatographic assay thereof employing superparamagnetic particles throughtout
JP2006255817A (en) * 2005-03-16 2006-09-28 Sonac Kk Metal structure and its manufacturing method
EP1937829A4 (en) 2005-09-26 2011-08-03 Rapid Micro Biosystems Inc Cassette containing growth medium
CN102224260B (en) * 2008-09-24 2015-11-25 施特劳斯控股公司 For test kit and the device of detect analytes
JP5578241B2 (en) * 2010-12-21 2014-08-27 株式会社島津製作所 Device and method for manipulating a target component in a tube
HUE036509T2 (en) 2011-11-07 2018-07-30 Rapid Micro Biosystems Inc Cassette for sterility testing
US10407707B2 (en) 2012-04-16 2019-09-10 Rapid Micro Biosystems, Inc. Cell culturing device
US9657290B2 (en) * 2012-07-03 2017-05-23 The Board Of Trustees Of The Leland Stanford Junior University Scalable bio-element analysis
EP3828284A1 (en) 2013-03-15 2021-06-02 Abbott Molecular Inc. One-step procedure for the purification of nucleic acids
WO2015046293A1 (en) * 2013-09-30 2015-04-02 凸版印刷株式会社 Test substance detection system
US10370653B2 (en) 2015-02-22 2019-08-06 The Board Of Trustees Of The Leland Stanford Junior University Micro-screening apparatus, process, and products
CN115254210A (en) 2016-11-14 2022-11-01 浩康生物系统公司 Method and apparatus for sorting target particles
CN107192818B (en) * 2017-05-23 2018-06-29 重庆天之助生物科技有限公司 A kind of particulate coloration clustering method and kit
WO2019204784A1 (en) * 2018-04-19 2019-10-24 First Light Biosciences, Inc. Detection of targets

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1566098A (en) * 1975-11-14 1980-04-30 Nat Res Dev Separation of solid and liquid components of mixtures
US4115535A (en) * 1977-06-22 1978-09-19 General Electric Company Diagnostic method employing a mixture of normally separable protein-coated particles
CA1111762A (en) * 1977-12-28 1981-11-03 David S. Frank Fluorescent rare earth chelate in polymeric latex particles
US4434150A (en) * 1981-10-19 1984-02-28 Ortho Diagnostic Systems, Inc. Immunological reagents employing polymeric backbone possessing reactive functional groups
GB8401368D0 (en) * 1984-01-19 1984-02-22 Amersham Int Plc Assay method
FI841023A0 (en) * 1984-03-14 1984-03-14 Labsystems Oy FOERFARANDE FOER UTFOERING AV IMMUNOBESTAEMNINGAR
FI842992A0 (en) * 1984-07-26 1984-07-26 Labsystems Oy IMMUNOLOGISKT DEFINITIONSFOERFARANDE.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8604684A1 *

Also Published As

Publication number Publication date
FI850481A0 (en) 1985-02-06
JPS62501647A (en) 1987-07-02
WO1986004684A1 (en) 1986-08-14

Similar Documents

Publication Publication Date Title
EP0214167A1 (en) Method for the determination of antibodies or antigens
US5558839A (en) Magnetic device for immunological analysis of a solid phase
US4777145A (en) Immunological assay method using magnetic particles
US5374531A (en) Immunoassay for determination of cells
US5145784A (en) Double capture assay method employing a capillary flow device
US4098876A (en) Reverse sandwich immunoassay
EP0149565B1 (en) Assay method
US4659678A (en) Immunoassay of antigens
US5501949A (en) Particle bound binding component immunoassay
EP0559738B1 (en) Methods for detection and quantitation of cell subsets within subpopulations of a mixed cell population
US20090087869A1 (en) Sandwich immunoassay and method of detecting an antigen by using the same
JPH08501145A (en) Solid-phase immunoassay
JPH09504094A (en) Method for assaying immunological substances using magnetic latex particles and non-magnetic particles
EP0397659A4 (en) Process for detecting biochemical species and apparatus useful therein
EP1347301A1 (en) Method for ultra-rapid and ultra-sensitive measurement
Helmberg et al. Detection and differentiation of platelet‐specific antibodies by flow cytometry: the bead‐mediated platelet assay
WO1989011102A1 (en) Capillary flow device and double capture assay method
JPH046464A (en) Immunological examination method
Llopis et al. A new microplate red blood cell monolayer technique for screening and identifying red blood cell antibodies
CA2035305A1 (en) Immunochemical assay method with plural items
JPH04203968A (en) Method for measuring chemical emission immunity
Miyai Classification of immunoassay
JPH0244254A (en) Multiple parameter particle analysis
Salomons et al. Immunoassay: A survey of patents, patent applications and other literature 1980-1991
JPH07333225A (en) Immunoassay enhanced in sensitivity

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19860903

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19881215

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 19891214

RIN1 Information on inventor provided before grant (corrected)

Inventor name: LUOTOLA, JUHANI, E.I.

Inventor name: HARJUNMAA, HANNU